Ganglioglioma with adverse clinical outcome and atypical histopathological features were defined by alterations in PTPN11/KRAS/NF1 and other RAS-/MAP-Kinase pathway genes

MLA

Lucas Hoffmann, et al. “Ganglioglioma with Adverse Clinical Outcome and Atypical Histopathological Features Were Defined by Alterations in PTPN11/KRAS/NF1 and Other RAS-/MAP-Kinase Pathway Genes.” Acta Neuropathologica, vol. 145, Mar. 2023, pp. 815–27. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b6d6b418e8446fc02178c4ee9db7301f&authtype=sso&custid=ns315887.

APA

Lucas Hoffmann, Roland Coras, Katja Kobow, Javier A. López-Rivera, Dennis Lal, Costin Leu, Imad Najm, Peter Nürnberg, Jochen Herms, Patrick N. Harter, Christian G. Bien, Thilo Kalbhenn, Markus Müller, Tom Pieper, Till Hartlieb, Manfred Kudernatsch, Hajo Hamer, Sebastian Brandner, Karl Rössler, … Samir Jabari. (2023). Ganglioglioma with adverse clinical outcome and atypical histopathological features were defined by alterations in PTPN11/KRAS/NF1 and other RAS-/MAP-Kinase pathway genes. Acta Neuropathologica, 145, 815–827.

Chicago

Lucas Hoffmann, Roland Coras, Katja Kobow, Javier A. López-Rivera, Dennis Lal, Costin Leu, Imad Najm, et al. 2023. “Ganglioglioma with Adverse Clinical Outcome and Atypical Histopathological Features Were Defined by Alterations in PTPN11/KRAS/NF1 and Other RAS-/MAP-Kinase Pathway Genes.” Acta Neuropathologica 145 (March): 815–27. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b6d6b418e8446fc02178c4ee9db7301f&authtype=sso&custid=ns315887.